NantOmics to Present Data on Using GPS Cancer Proteomic Analysis to Inform Metastatic Colorectal Cancer Patient Treatment with Temozolomide at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting

Results to be presented during tumor biology session at the ASCO 2017 Annual Meeting

CHICAGO--()--NantWorks, LLC today announced that its affiliate company, NantOmics, LLC, the leader in molecular diagnostics and a member of the NantWorks ecosystem of families, will present findings on how the GPS cancer quantitative proteomic analysis can help guide metastatic colorectal cancer (mCRC) patient selection for treatment with temozolomide (TMZ) during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, an event bringing together 30,000 oncology professionals from June 2-6, 2017 at McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at booth #19135 during the event.

“We’re thrilled to be able to share positive data on the benefits of leveraging GPS Cancer's quantitative proteomic analysis to determine treatment options in patients with metastatic colorectal cancer,” said Patrick Soon-Shiong, MD, founder of NantWorks. “Temozolomide has historically been a standard treatment in patients with melanoma and glioblastoma and now we’re able to take these findings and apply them to other cancer types through quantitative proteomic analysis. This is an exciting step that brings us closer to achieving our goal of tailoring treatments based on an individual’s molecular profile and extending from genomics to proteomics, driving actionable information before treatment begins.”

Presentation Details
Selecting patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of MGMT, Abstract #11601

WHO:

    NantOmics, LLC

WHAT:

Tumor Biology Session

WHEN:

June 3, 1:15-4:45 PM CT

WHERE:

Hall A, McCormick Place
 

Presentation Summary
The study was conducted to test whether mCRC patients whose tumors expressed quantities of MGMT (a DNA repair protein) below a pre-defined amount would have better outcomes following TMZ treatment compared to patients with MGMT levels that exceeded the amount. The results showed that patients whose tumors expressed low or undetectable levels of MGMT experienced better outcomes with TMZ treatment compared to their counterparts, demonstrating that quantitative proteomic analysis could be used to determine which mCRC patients are fit to receive TMZ treatment.

About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About NantWorks
NantWorks, LLC, founded by renowned physician scientist and inventor of the first human nanoparticle chemotherapeutic agent Abraxane®, Dr. Patrick Soon-Shiong, is the umbrella organization for the following entities: NantHealth, NantMobileHealth, NantOmics, NantBio, NantCell, NantPharma, NantCapital and NantCloud. Fact-based and solution-driven, each of NantWorks’ division entities operates at the nexus of innovation and infrastructure. The core mission of NantWorks is convergence and a systems approach to human biology: to develop and deliver a diverse range of technologies that accelerates innovation, broaden the scope of scientific discovery, enhance ground-breaking research, and improve healthcare treatment for those in need. NantWorks is building an integrated fact-based, genomically and proteomically informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics for life threatening diseases such as Cancer, Infectious Diseases and Alzheimer’s. For more information please visit www.nantworks.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.

About GPS Cancer™
GPS Cancer™ is a unique, comprehensive test available through NantHealth. GPS Cancer integrates whole genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and quantitative proteomics through mass spectrometry, providing oncologists with a comprehensive molecular profile of a patient’s cancer to inform personalized treatment strategies. GPS Cancer testing is conducted in CLIA-certified and CAP-accredited laboratories, and is a key enabler for Cancer Breakthroughs 2020, the world’s most comprehensive cancer collaborative initiative seeking to accelerate the potential of combination immunotherapy as the next generation standard of care in cancer patients. For more information, visit www.gpscancer.com and www.cancerbreakthroughs2020.org.

Contacts

NantWorks
Jen Hodson, 562-397-3639
jhodson@nantworks.com

Contacts

NantWorks
Jen Hodson, 562-397-3639
jhodson@nantworks.com